ArticleOncoimmunology2023

Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer.

Maximilian Marhold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.